PH30168A - N-oxycarbonyl substituted 5'-doxy-5-fluorcytidines - Google Patents

N-oxycarbonyl substituted 5'-doxy-5-fluorcytidines

Info

Publication number: PH30168A
Authority: PH; Philippines
Prior art keywords: radical; formula; integer; protecting groups; general formula
Prior art date: 1992-12-18

Application number

PH47455A

Other languages

English (en)

Inventor

Motohiro Arasaki

Hideo Ishitsuka

Isami Kuruma

Masanori Miwa

Chikako Murasaki

Nobuo Shimma

Isao Umeda

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-18

Filing date

1993-12-15

Publication date

1997-01-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH30168(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-12-15 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1997-01-21 Publication of PH30168A publication Critical patent/PH30168A/en

Links

150000001875 compounds Chemical class 0.000 abstract 3
-1 hydrocarbon radical Chemical class 0.000 abstract 3
239000004215 Carbon black (E152) Substances 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229930195733 hydrocarbon Natural products 0.000 abstract 2
125000006239 protecting group Chemical group 0.000 abstract 2
150000003254 radicals Chemical class 0.000 abstract 2
YSNABXSEHNLERR-ZIYNGMLESA-N 5'-Deoxy-5-fluorocytidine Chemical class O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(F)=C1 YSNABXSEHNLERR-ZIYNGMLESA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 abstract 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicinal Preparation (AREA)

PH47455A 1992-12-18 1993-12-15 N-oxycarbonyl substituted 5'-doxy-5-fluorcytidines PH30168A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP92121538		1992-12-18

Publications (1)

Publication Number	Publication Date
PH30168A true PH30168A (en)	1997-01-21

Family

ID=8210304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH47455A PH30168A (en)	1992-12-18	1993-12-15	N-oxycarbonyl substituted 5'-doxy-5-fluorcytidines

Country Status (40)

Country	Link
US (1)	US5472949A (is)
EP (1)	EP0602454B1 (is)
JP (1)	JP2501297B2 (is)
KR (1)	KR100347218B1 (is)
CN (1)	CN1035617C (is)
AT (1)	ATE137244T1 (is)
AU (1)	AU671491B2 (is)
BG (1)	BG61485B1 (is)
BR (1)	BR9305089A (is)
CA (1)	CA2103324C (is)
CZ (1)	CZ284788B6 (is)
DE (1)	DE69302360T2 (is)
DK (1)	DK0602454T3 (is)
EE (1)	EE03086B1 (is)
ES (1)	ES2086856T3 (is)
FI (1)	FI112365B (is)
GE (1)	GEP20074251B (is)
GR (1)	GR3020286T3 (is)
HR (1)	HRP931430B1 (is)
HU (2)	HU218291B (is)
IL (1)	IL108000A0 (is)
IS (1)	IS4108A (is)
LT (1)	LT3115B (is)
LV (1)	LV10625B (is)
MY (1)	MY109282A (is)
NO (1)	NO300066B1 (is)
NZ (1)	NZ250414A (is)
PH (1)	PH30168A (is)
PL (1)	PL174100B1 (is)
RO (1)	RO112619B1 (is)
RU (2)	RU2493162C1 (is)
SA (1)	SA93140409B1 (is)
SI (1)	SI9300648B (is)
SK (1)	SK281403B6 (is)
SV (1)	SV1993000080A (is)
TW (1)	TW372239B (is)
UA (1)	UA39158C2 (is)
UY (1)	UY23697A1 (is)
YU (1)	YU49411B (is)
ZA (1)	ZA939293B (is)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5476932A (en) *	1994-08-26	1995-12-19	Hoffmann-La Roche Inc.	Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) *	1997-06-02	2009-08-26	F. Hoffmann-La Roche Ag	5'-Deoxy-cytidine derivatives
NZ330360A (en) *	1997-06-02	1999-03-29	Hoffmann La Roche	5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) *	1998-02-06	1999-12-21	Hoffmann-La Roche Inc.	5'deoxycytidine derivatives
YU22401A (sh) *	1998-09-25	2004-03-12	Warner-Lambert Company	Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) *	1998-11-02	2007-05-31	Elan Corporation Plc	Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
KR100717916B1 (ko) *	2000-02-28	2007-05-11	아방티 파르마 소시에테 아노님	캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
AU2001246863A1 (en) *	2000-04-11	2001-10-23	Sayuri Yamada	Curcumin compositions
KR100730768B1 (ko) *	2000-08-09	2007-06-21	코오롱생명과학 주식회사	5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) *	2000-08-09	2006-10-09	주식회사 코오롱	Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) *	2001-06-04	2001-07-25	Jerram Clare	Washing line umbrella
RU2346686C2 (ru) *	2002-01-14	2009-02-20	Новартис Аг	Комбинации, включающие эпотилоны и антиметаболиты
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
MXPA05003431A (es) *	2002-11-15	2005-07-05	Warner Lambert Co	Quimioterapia de combinacion.
AU2003233586A1 (en) *	2003-05-20	2005-01-21	Aronex Pharmaceuticals, Inc.	Combination chemotherapy comprising capecitabine and a liposomal platinum complex
SI1689404T1 (sl) *	2003-11-13	2009-02-28	Pharma Mar Sau	Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CA2550299C (en) *	2003-12-22	2010-03-30	Christopher R. Roberts	Process for fluorocytidine derivatives
CN108421044A (zh)	2005-02-03	2018-08-21	综合医院公司	治疗吉非替尼耐药性癌症的方法
AU2006228581A1 (en) *	2005-04-01	2006-10-05	F. Hoffmann-La Roche Ag	Method for administration of capecitabine
RU2447889C2 (ru)	2005-07-18	2012-04-20	Бипар Сайенсиз, Инк.	Способ лечения рака (варианты)
WO2007009245A1 (en)	2005-07-21	2007-01-25	Nuvo Research Inc.	Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
CN103214484B (zh)	2005-12-13	2016-07-06	因塞特控股公司	作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US20100160442A1 (en) *	2006-07-18	2010-06-24	Ossovskaya Valeria S	Formulations for cancer treatment
US20080085310A1 (en) *	2006-10-06	2008-04-10	Maria Oksana Bachynsky	Capecitabine rapidly disintegrating tablets
CN100425617C (zh) *	2006-10-31	2008-10-15	浙江海正药业股份有限公司	一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it)	2007-03-05	2008-09-06	Innovate Biotechnology Srl	2',3'-di-o-acil-5-fluoronucleosidi
US20100130734A1 (en) *	2007-04-20	2010-05-27	Dr. Reddy's Laboratories Ltd.	Process for preparing capecitabine
EP2164856A1 (en) *	2007-06-01	2010-03-24	Synthon B.V.	Processes related to making capecitabine
HUE029236T2 (en)	2007-06-13	2017-02-28	Incyte Holdings Corp	(R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
US7842675B2 (en) *	2007-09-15	2010-11-30	Protia, Llc	Deuterium-enriched capecitabine
WO2009042064A2 (en)	2007-09-21	2009-04-02	Nektar Therapeutics Al, Corporation	Oligomer-nucleoside phosphate conjugates
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) *	2007-11-19	2011-02-09	한미홀딩스 주식회사	카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es)	2007-12-06	2009-03-18	Richmond Sa Com Ind Y Financie	Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009088989A1 (en) *	2008-01-03	2009-07-16	Plus Chemicals, S.A.	Process for the preparation of capecitabine
US20090311335A1 (en) *	2008-06-12	2009-12-17	Scott Jenkins	Combination of a triptan and an nsaid
CN102641270A (zh)	2008-06-17	2012-08-22	惠氏有限责任公司	含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en)	2008-08-04	2014-03-11	Wyeth Llc	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010065586A2 (en) *	2008-12-02	2010-06-10	Dr. Reddy's Laboratories Ltd.	Preparation of capecitabine
WO2010063080A1 (en) *	2008-12-05	2010-06-10	Commonwealth Scientific And Industrial Research Organisation	Amphiphile prodrugs
IL264349B2 (en)	2009-04-06	2024-01-01	Wyeth Llc	Regimen comprising neratinib for the treatment of cancer
FR2945211A1 (fr)	2009-05-06	2010-11-12	Sanofi Aventis	Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EP2432472B1 (en)	2009-05-22	2019-10-02	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
KR20120037932A (ko) *	2009-07-23	2012-04-20	시노팜 타이완 리미티드	플루오로시티딘 유도체를 제조하는 방법
WO2011067588A1 (en)	2009-12-04	2011-06-09	Generics [Uk] Limited	Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) *	2010-02-24	2011-09-01	Generics [Uk] Limited	One step process for the preparation of capecitabine
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TR201816180T4 (tr)	2010-03-12	2018-11-21	Genzyme Corp	Meme kanserini tedavi etmek için kombinasyonlu tedavi.
AR084691A1 (es)	2010-05-21	2013-06-05	Incyte Corp	Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CN102260309B (zh) *	2010-05-24	2014-10-22	重庆福安药业(集团)股份有限公司	一种高纯度卡培他滨的制备方法
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102558262A (zh) *	2010-12-23	2012-07-11	天津泰普药品科技发展有限公司	一种高纯度卡培他滨的制备方法
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102266303A (zh) *	2011-07-07	2011-12-07	程雪翔	一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) *	2011-12-09	2014-04-02	海南锦瑞制药股份有限公司	一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) *	2012-01-13	2016-12-01	Pharmaessentia Corp	Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
TWI761825B (zh)	2012-11-15	2022-04-21	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
MX384910B (es)	2013-03-06	2025-03-14	Incyte Holdings Corp	Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en)	2013-08-07	2016-03-30	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
WO2015026818A1 (en) *	2013-08-20	2015-02-26	Incyte Corporation	Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en)	2013-12-13	2015-06-17	Plasmia Biotech, S.L.	Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) *	2013-12-18	2014-07-02	吉林修正药业新药开发有限公司	一种卡培他滨异构体的制备方法
WO2015191576A1 (en)	2014-06-09	2015-12-17	Lipomedix Pharmaceuticals Ltd.	Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CN104530164A (zh) *	2014-12-31	2015-04-22	辰欣药业股份有限公司	一种卡培他滨的合成工艺
KR20160117060A (ko)	2015-03-31	2016-10-10	이승주	유아용 탁자
CN105646625B (zh) *	2015-12-29	2019-06-11	江苏吴中医药集团有限公司	一种卡培他滨的制备方法
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
EP3565549B1 (en)	2017-01-09	2022-03-09	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) *	2017-02-20	2017-07-21	Anadolu Ueniversitesi	Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en)	2017-10-03	2019-10-08	Nucorion Pharmaceuticals, Inc.	5-fluorouridine monophosphate cyclic triester compounds
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3737376B1 (en)	2018-01-09	2024-04-17	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human diseases
CN111836818B (zh)	2018-01-10	2023-10-31	纽科利制药公司	氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
WO2019143860A1 (en) *	2018-01-19	2019-07-25	Nucorion Pharmaceuticals, Inc.	5-fluorouracil compounds
US11427550B2 (en)	2018-01-19	2022-08-30	Nucorion Pharmaceuticals, Inc.	5-fluorouracil compounds
JP7393348B2 (ja)	2018-01-30	2023-12-06	インサイト・コーポレイション	（１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh)	2018-03-30	2021-12-10	因赛特公司	使用jak抑制剂治疗化脓性汗腺炎
US12171746B2 (en)	2019-01-11	2024-12-24	Lipomedix Pharmaceuticals Ltd.	Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
EP3999519A4 (en)	2019-07-17	2023-08-16	Nucorion Pharmaceuticals, Inc.	CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
WO2021216427A1 (en)	2020-04-21	2021-10-28	Ligand Pharmaceuticals, Inc.	Nucleotide prodrug compounds
EP4139319A4 (en)	2020-04-21	2024-06-19	Ligand Pharmaceuticals, Inc.	BENZYLOXY-PHOSPH(ON)ATE COMPOUNDS
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022047400A1 (en)	2020-08-31	2022-03-03	Emory University	5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
WO2023177894A1 (en)	2022-03-18	2023-09-21	Ideaya Biosciences, Inc.	Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (en)	2022-12-05	2025-08-27	a Fine House S.A.	Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1135258A (en) *	1979-06-15	1982-11-09	Richard D'souza	Process for the preparation of 5'deoxy-5-fluorouridine
DE3587500T2 (de) *	1984-12-04	1993-12-16	Lilly Co Eli	Tumorbehandlung bei Säugetieren.
CA1327358C (en) *	1987-11-17	1994-03-01	Morio Fujiu	Fluoro cytidine derivatives

1993
- 1993-11-12 AU AU50690/93A patent/AU671491B2/en not_active Expired
- 1993-11-15 TW TW082109533A patent/TW372239B/zh not_active IP Right Cessation
- 1993-11-17 CA CA002103324A patent/CA2103324C/en not_active Expired - Lifetime
- 1993-11-23 HR HR92121538.0A patent/HRP931430B1/xx not_active IP Right Cessation
- 1993-12-01 EP EP93119349A patent/EP0602454B1/en not_active Expired - Lifetime
- 1993-12-01 DK DK93119349.4T patent/DK0602454T3/da active
- 1993-12-01 AT AT93119349T patent/ATE137244T1/de active
- 1993-12-01 DE DE69302360T patent/DE69302360T2/de not_active Expired - Lifetime
- 1993-12-01 ES ES93119349T patent/ES2086856T3/es not_active Expired - Lifetime
- 1993-12-07 SA SA93140409A patent/SA93140409B1/ar unknown
- 1993-12-10 SI SI9300648A patent/SI9300648B/sl unknown
- 1993-12-10 ZA ZA939293A patent/ZA939293B/xx unknown
- 1993-12-10 HU HU9303525A patent/HU218291B/hu active Protection Beyond IP Right Term
- 1993-12-10 NZ NZ250414A patent/NZ250414A/en not_active IP Right Cessation
- 1993-12-13 IL IL10800093A patent/IL108000A0/xx not_active IP Right Cessation
- 1993-12-13 CZ CZ932731A patent/CZ284788B6/cs not_active IP Right Cessation
- 1993-12-14 FI FI935616A patent/FI112365B/fi not_active IP Right Cessation
- 1993-12-14 US US08/167,392 patent/US5472949A/en not_active Expired - Lifetime
- 1993-12-15 RO RO93-01706A patent/RO112619B1/ro unknown
- 1993-12-15 YU YU77993A patent/YU49411B/sh unknown
- 1993-12-15 PH PH47455A patent/PH30168A/en unknown
- 1993-12-16 RU RU2012134029/04A patent/RU2493162C1/ru not_active IP Right Cessation
- 1993-12-16 RU RU93056196/04A patent/RU2458932C2/ru active Protection Beyond IP Right Term
- 1993-12-16 BG BG98304A patent/BG61485B1/bg unknown
- 1993-12-16 BR BR9305089A patent/BR9305089A/pt not_active Application Discontinuation
- 1993-12-16 KR KR1019930027962A patent/KR100347218B1/ko not_active Expired - Lifetime
- 1993-12-16 JP JP5342812A patent/JP2501297B2/ja not_active Expired - Fee Related
- 1993-12-16 MY MYPI93002726A patent/MY109282A/en unknown
- 1993-12-17 LV LVP-93-1347A patent/LV10625B/en unknown
- 1993-12-17 PL PL93301541A patent/PL174100B1/pl unknown
- 1993-12-17 SV SV1993000080A patent/SV1993000080A/es not_active Application Discontinuation
- 1993-12-17 CN CN93112838A patent/CN1035617C/zh not_active Expired - Lifetime
- 1993-12-17 SK SK1444-93A patent/SK281403B6/sk not_active IP Right Cessation
- 1993-12-17 LT LTIP1627A patent/LT3115B/lt not_active IP Right Cessation
- 1993-12-17 IS IS4108A patent/IS4108A/is unknown
- 1993-12-17 NO NO934671A patent/NO300066B1/no not_active IP Right Cessation
- 1993-12-17 UA UA93004687A patent/UA39158C2/uk unknown
- 1993-12-17 UY UY23697A patent/UY23697A1/es not_active IP Right Cessation
1994
- 1994-11-18 EE EE9400154A patent/EE03086B1/xx not_active IP Right Cessation
1995
- 1995-06-19 HU HU95P/P00255P patent/HU211965A9/hu unknown
1996
- 1996-06-19 GR GR960401668T patent/GR3020286T3/el unknown
2006
- 2006-07-17 GE GEAP20069525A patent/GEP20074251B/en unknown

Also Published As

Publication number	Publication date
NO934671D0 (no)	1993-12-17
SV1993000080A (es)	1996-01-26
IL108000A0 (en)	1994-04-12
ZA939293B (en)	1994-06-18
FI935616L (fi)	1994-06-19
GR3020286T3 (en)	1996-09-30
SI9300648B (sl)	2000-06-30
HU211965A9 (en)	1996-01-29
RO112619B1 (ro)	1997-11-28
PL174100B1 (pl)	1998-06-30
JP2501297B2 (ja)	1996-05-29
CZ273193A3 (en)	1994-07-13
MY109282A (en)	1996-12-31
HRP931430B1 (en)	1999-08-31
NO300066B1 (no)	1997-04-01
UY23697A1 (es)	1994-06-08
HU9303525D0 (en)	1994-04-28
LT3115B (en)	1994-12-27
BG98304A (bg)	1994-01-03
CZ284788B6 (cs)	1999-03-17
GEP20074251B (en)	2007-12-10
US5472949A (en)	1995-12-05
EP0602454B1 (en)	1996-04-24
RU2458932C2 (ru)	2012-08-20
CA2103324A1 (en)	1994-06-19
IS4108A (is)	1994-06-19
SK144493A3 (en)	1994-10-05
PL301541A1 (en)	1994-06-27
ES2086856T3 (es)	1996-07-01
AU5069093A (en)	1994-06-30
EE03086B1 (et)	1998-04-15
UA39158C2 (uk)	2001-06-15
BG61485B1 (bg)	1997-09-30
RU2135511C1 (ru)	1999-08-27
CN1094056A (zh)	1994-10-26
RU2493162C1 (ru)	2013-09-20
HK1005875A1 (en)	1999-01-29
AU671491B2 (en)	1996-08-29
LV10625A (lv)	1995-04-20
SI9300648A (en)	1994-09-30
JPH06211891A (ja)	1994-08-02
DE69302360D1 (de)	1996-05-30
FI935616A0 (fi)	1993-12-14
LV10625B (en)	1996-04-20
EP0602454A1 (en)	1994-06-22
TW372239B (en)	1999-10-21
HRP931430A2 (en)	1998-06-30
LTIP1627A (en)	1994-07-15
BR9305089A (pt)	1994-07-05
CA2103324C (en)	1997-12-23
FI112365B (fi)	2003-11-28
NO934671L (no)	1994-06-20
NZ250414A (en)	1995-12-21
YU77993A (sh)	1996-10-18
SA93140409B1 (ar)	2004-07-24
SK281403B6 (sk)	2001-03-12
KR940014428A (ko)	1994-07-18
CN1035617C (zh)	1997-08-13
YU49411B (sh)	2006-01-16
HU218291B (en)	2000-07-28
HUT65757A (en)	1994-07-28
ATE137244T1 (de)	1996-05-15
DE69302360T2 (de)	1996-10-31
KR100347218B1 (ko)	2003-01-24
DK0602454T3 (da)	1996-07-29

Publication	Publication Date	Title
GR3020286T3 (en)	1996-09-30	N-oxycarbonyl substituted 5'-deoxy-5-fluorocytidines.
RU93056196A (ru)	1997-03-27	N-карбонилзамещенные 5'-дезокси-5-фторцитидина
EG18944A (en)	1994-06-30	(Benzylidene) - Azolylmethylcycloalkane and use as fungicide
HU9203016D0 (en)	1992-12-28	New taxane compounds substituted with alkoxy and pharmaceutical preparatives containing these compounds
DE68905627D1 (de)	1993-05-06	Hydrophile sauerstoffdurchlaessige polymere.
MX9704449A (es)	1997-12-31	Compuestos de aminosilano en composiciones de caucho cargadas con silice.
GR3007983T3 (is)	1993-08-31
SG52704A1 (en)	1998-09-28	Specamycin derivatives and the use thereof
HU9401976D0 (en)	1994-09-28	N,n'-substituted imidocarbonimidic diamides, pharmaceutical compositions containing them and use of these compounds aganst infection
CA2065978A1 (en)	1992-11-17	Organosilicon compounds containing (meth)acryloxy groups, their preparation and use
TW230771B (is)	1994-09-21
TW216770B (is)	1993-12-01
EP0401715A3 (en)	1992-03-04	Aminoketone compounds
AU3093689A (en)	1989-09-07	Adhesive